Mesoblast Limited (ASX:MSB; USOTC:MBLTY)

Melbourne Australia

Medical / Health Care / Pharmaceuticals

Mesoblast Limited (ASX:MSB; USOTC:MBLTY) is developing novel biotherapeutics derived from its proprietary cell-based technologies. These technology platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat a broad range of conditions with major unmet medical needs. The Company’s technology platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat a broad range of conditions with major unmet medical needs. Its strategic product development focus is in four major and distinct areas - systemic inflammatory conditions, cardiovascular diseases, orthopedic diseases of the spine and oncology conditions.